NEW YORK, Oct. 3 /PRNewswire-FirstCall/ -- Xenomics, Inc. , the source of next-generation medical DNA diagnostic tests, recently provided a comprehensive business update in an interview with WallStreetReporter. Dr. David Tomei, CEO and Co-Founder of Xenomics, discussed the Company’s proprietary DNA diagnostic technology, product development initiatives, and Dr. David Sidransky, a new member of the Board of Directors.
“Xenomics has a revolutionary new approach to molecular diagnostic testing that uses simple and safe urine specimens in place of invasive and hazardous specimens including blood, sputum, or tissue biopsies,” summarized Dr. Tomei. “It has been demonstrated in clinical studies that our non-invasive urine test is capable of detecting DNA markers from throughout the body, is highly sensitive, and has the capacity to reveal the genetic signature of a broad range of diseases and conditions.”
The interview provides an in-depth discussion of Xenomics’ revolutionary DNA diagnostic technology and its advantages over existing methods and practices, its strong intellectual property position, market opportunities, product development initiatives, and how strategic partnerships and alliances fit into the Company’s overall growth strategy.
“We are also very pleased to have Dr. David Sidransky from Johns Hopkins University join our Board of Directors,” commented Dr. Tomei. “He is a highly-accomplished, well-known professor of oncology, urology, cellular, and molecular medicine. He has an extraordinary combination of unique medical expertise, practical business experience, and effective leadership skills. His acceptance of our Board seat demonstrates confidence in Xenomics and its technology from a person who is highly-accomplished and recognized worldwide.”
You can listen to this interview and obtain a complete transcript at http://www.wallstreetreporter.com/profile.php?id=20601.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using transrenal DNA. Xenomics’ patented technology uses safe and simple urine specimens and is being applied to a broad range of applications including detection and monitoring of infectious diseases, tumor detection and therapeutic monitoring, stem cell transplantation monitoring, and prenatal genetic testing. Scientists from Xenomics were the first to discover that fragments of DNA from cells throughout the body can cross the kidney barrier and be readily detected in small urine specimens. The Company believes that its transrenal DNA technology will open significant new markets in the molecular diagnostics field and provide a new generation of molecular diagnostic tests. Xenomics’ issued U.S. patents protect an array of applications for molecular diagnostics and genetic testing. The Company has been joined by the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive “Lazarus Spallanzani”) in Rome, in formation of a research and development company called SpaXen Italia, S.R.L, where clinical researchers are focused on transrenal DNA diagnostics for a variety of infectious diseases. For additional information, please visit www.xenomics.com. Xenomics’ stock trades under the symbol XNOM.OB and is also listed on the Frankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as “expect,” “might,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward- looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics’ Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics’ technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Contact: Xenomics, Inc. L. David Tomei 212-297-0808 ldtomei@xenomics.comwww.xenomics.com
Xenomics, Inc.
CONTACT: L. David Tomei, Xenomics, Inc., +1-212-297-0808,ldtomei@xenomics.com
Web site: http://www.xenomics.com//
